| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYST3 |
| Uniprot No | Q92794 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 81-179 aa |
| 活性数据 | ALPKPRNHGKLDNKQNVDWNKLIKRAVEGLAESGGSTLKSIERFLKGQKDVSALFGGSAASGFHQQLRLAIKRAIGHGRLLKDGPLYRLNTKATNVDGK |
| 分子量 | 36.63 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"KAT6A (MYST3) acetyltransferase is a key regulator of the leucine-rich repeat kinase 2 (LRRK2) promoter"**
*作者：Huang et al. (2018)*
摘要：研究探讨了重组人MYST3蛋白在乙酰化组蛋白H3中的作用，并发现其通过表观遗传机制调控LRRK2基因表达，可能与神经退行性疾病相关。
2. **"Structural insights into the recognition of histone H3K4me3 by the MYST3 acetyltransferase complex"**
*作者：Wang et al. (2016)*
摘要：通过解析重组MYST3蛋白与伴侣蛋白BRPF1的复合体结构，揭示了其识别H3K4me3标记并催化组蛋白H3乙酰化的分子机制，阐明了其在染色质修饰中的功能。
3. **"MYST3 regulates leukemia stem cell-like properties in acute myeloid leukemia"**
*作者：Li et al. (2020)*
摘要：研究发现重组MYST3蛋白通过乙酰化非组蛋白靶标(如转录因子RUNX1)维持白血病干细胞自我更新能力，为AML的靶向治疗提供理论依据。
4. **"The MYST family histone acetyltransferase KAT6A interacts with the DNA replication licensing factor Cdt1"**
*作者：Li et al. (2019)*
摘要：研究首次报道重组人MYST3与DNA复制调控蛋白Cdt1的直接互作，表明其可能在细胞周期调控和基因组稳定性维持中具有双重功能。
MYST3 (also known as KAT6A or MOZ) is a member of the MYST family of histone acetyltransferases (HATs), which play critical roles in epigenetic regulation by acetylating lysine residues on histones. This post-translational modification facilitates chromatin relaxation, enabling transcriptional activation. MYST3 is particularly notable for its involvement in embryonic development, cellular differentiation, and proliferation. Structurally, it contains an N-terminal acetyltransferase domain and C-terminal motifs that mediate interactions with regulatory partners like BRPF1/2/3 and ING5. forming multiprotein complexes essential for its HAT activity.
Dysregulation of MYST3 is implicated in hematological malignancies and solid tumors. Chromosomal translocations generating oncogenic fusion proteins (e.g., MOZ-TIF2 in acute myeloid leukemia) disrupt its normal function, altering gene expression programs. Additionally, heterozygous mutations in MYST3 are linked to genetic disorders such as KAT6A syndrome, characterized by developmental delays and congenital anomalies.
Recombinant MYST3 protein, produced via heterologous expression systems like bacteria or mammalian cells, serves as a vital tool for studying its enzymatic activity, substrate specificity, and interactions. Researchers utilize it to explore molecular mechanisms in cancer biology, screen for HAT inhibitors, or model disease-associated mutations. Its role in balancing self-renewal and differentiation in stem cells further underscores its therapeutic relevance. As epigenetic therapies gain traction, understanding MYST3’s function offers insights into targeting chromatin-modifying enzymes for diseases driven by transcriptional dysregulation.
×
